Clinical trial · Observational
Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
No structured organization for ovarian first line management emerges in France. Management across France seems to depend on regional contexts. Regions display no specific organization or delineate regional network for the ovarian cancer management or report centralized management revolving around referent centers. These different templates present a major problem in identifying differences, costs and benefit. To deal with this issue the Investigators propose a health economic evaluation based on cost-effectiveness analyses, completed with a budget impact analysis. This study will investigate the cost-effective management of patients with initial ovarian cancer using databases representative of different parts of French territories.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Epithelial Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient with ovarian epithelial cancer | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patient with ovarian epithelial cancer
- description
- Ovarian epithelial cancer diagnosed in 2012
- interventionNames
- Other: Patient with ovarian epithelial cancer
Primary outcomes (1)
- measure
- Incremental cost-effectiveness ratio expressed in cost per relapse-free year gained
- timeFrame
- 2 years after diagnosis
- description
- To perform a cost-effectiveness analysis in order to evaluate the most efficient organization for ovarian cancer in 1st line ot treatment
Secondary outcomes (3)
- measure
- Incremental cost-effectiveness ratio expressed in cost per QALY(Quality-Adjusted Life Year) gained.
- timeFrame
- 2 years after diagnosis
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Ovarian epithelial cancer initially diagnosed in 2012 * Age \> 18 years old * Residency in France (Rhône-Alpes region, District of Calvados and Cotes d'Or) * First-line ovarian epithelial cancer Exclusion Criteria: * Relapsed ovarian epithelial cancer * Non epithelial ovarian cancer
References
Publications (0)
Data not yet available